Summary
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation, however, have dissuaded investigators from conducting these studies as often as their utility may merit. Accelerator mass spectrometry (AMS), originally designed for carbon dating and geochronology, has changed the outlook for in-human radiolabeled testing.
Register to download
Opportunities in low-level radiocarbon microtracing: applications and new technology
You may also be interested in:
White Paper
Pharmacogenomics in Pain Management
Pharmacogenomics in Pain Management. In the US alone there are an estimated 100 million adults suffering from chronic pain. Pharmacogenomics and…
Capability
ECG Assessments in Renal and Hepatic Impaired Patients
PRA’s dedicated early phase professionals leverage proven expertise in renal and hepatic impairment to provide clients with high quality ECG…
Case Study
Recruiting Solid Tumor Patients in a Complex ADME Trial
PRA's PPS facility in Budapest (PPS-Hungary) was contracted to run an open-label, non-randomized, Phase I study to characterize the mass balance and…